Antibody therapeutics companies develop engineered antibodies that target specific molecules involved in disease. These medicines are used across oncology, autoimmune disease, inflammatory conditions, infectious disease and other areas of clinical development.
This category includes companies working on:
Browse 75 UK antibody therapeutics companies below.
Targeted antibody therapeutics for cancer and autoimmune disease
Medannex is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics targeting annexin-A1, a protein implicated in cancer progression, autoimmunity, and inflammation. Its lead asset, MDX-124, is the first therapeutic antibody to target annexin-A1 and is currently being evaluated in the…
Biologic therapies for autoinflammatory and autoimmune diseases
Kiniksa Pharmaceuticals International is a commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising medicines for autoinflammatory and autoimmune diseases with significant unmet need. Its approved product, rilonacept, is an IL-1 inhibitor indicated for recurrent pericarditis. The…
Bispecific antibody-drug conjugates for cancer-selective precision therapy
BiVictriX Therapeutics is a biopharmaceutical company developing bispecific antibody-drug conjugates for targeted cancer treatment. Its Bi-Cygni platform recognises combinations of two tumour-associated antigens to improve cancer-cell selectivity and limit effects on healthy tissues. Its lead solid-tumour candidate,…
Multispecific immune cell engagers targeting gamma delta T cells
Cytospire Therapeutics is developing multispecific engager antibodies designed to enhance and direct the activity of gamma delta T cells for the treatment of cancer and autoimmune disease. The company emerged from stealth in 2024, backed by Abingworth, 4BIO Capital and LifeArc Ventures. Its platform targets both…
VNAR antibody shuttles for brain-targeted biologic therapies
Ossianix is a biopharmaceutical company developing single-domain VNAR antibody platforms for targeted delivery of therapeutics across the blood-brain barrier. Its TXP1 shuttle binds transferrin receptor 1 to transport antibody-based medicines into the central nervous system. The company engineers antibody fusions and…
Specialty biopharma with UK neurotoxin manufacturing hub
Ipsen is a French specialty biopharmaceutical company with one of three global hubs based in the UK. Its Wrexham site serves as the company's global neuroscience centre of excellence, responsible for research, development and manufacture of neurotoxin products including botulinum toxin. The London site houses…
Shark-derived single-domain antibody biologics for cancer and inflammation
Elasmogen is a biotechnology company developing next-generation therapeutic biologics based on its proprietary soloMER platform, single-domain antibody-like proteins derived from the shark immune system. soloMERs offer advantages over conventional antibodies in size, stability, and tissue penetration. The pipeline…
Biparatopic PD-1/VEGFR2 antibody for solid tumour oncology
Ottimo Pharma is a clinical-stage biotechnology company developing biparatopic antibody therapeutics for solid tumour cancers. Its lead programme, Jankistomig, is a first-in-class single-agent IgG antibody that simultaneously targets PD-1 for immune checkpoint inhibition and VEGFR2 to suppress tumour angiogenesis. The…
Therapeutic antibodies targeting the angiotensin AT1R pathway in cancer
aTen Therapeutics is a Scottish pre-clinical biotechnology company developing therapeutic monoclonal antibodies against the angiotensin-II type I receptor (AT1R), which is overexpressed across a range of cancers. Its lead candidate, Tensinumab (ATN-E11), is a human monoclonal antibody generated via phage display that…
Cannabinoid medicines, neuroscience and oncology drug development
Jazz Pharmaceuticals is a global biopharmaceutical company focused on medicines for neuroscience and oncology. Its UK operations, centred at Kent Science Park in Sittingbourne, form the heart of its global cannabinoid manufacturing and research activities, inherited through its 2021 acquisition of GW Pharmaceuticals…
Pharmaceutical company in cardiometabolic, oncology, and immunology
Eli Lilly and Company is a multinational pharmaceutical company with UK operations headquartered in Basingstoke and an R&D site in Bracknell. Founded in 1876, Lilly's UK affiliate has operated since 1934 and employs approximately 700 people across regulatory, medical affairs, and research functions. The company…
Novel ADC payloads targeting NMT enzymes in cancer
Myricx Bio is a clinical-stage biotechnology company developing a novel class of antibody-drug conjugate payloads based on inhibition of N-myristoyltransferase, an enzyme essential to cancer cell survival. Its NMTi payload chemistry platform addresses limitations of existing ADC payloads, including resistance and…
VHH single-domain antibody therapeutics for companion animals and livestock
272Bio is a biotechnology company developing biotherapeutic treatments for animal health applications across livestock and companion animals. The company applies novel antibody engineering technologies, including VHH-based biologics, to create targeted and cost-effective therapies for veterinary diseases. 272Bio…
Antibody immunotherapy targeting toxic tau for neurodegenerative disease
TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in neurodegenerative disease. Its lead candidate, TBL-100, is a humanized monoclonal antibody developed with LifeArc, designed to selectively…
Finnish pharma company marketing and developing medicines
Orion Pharma (UK) Limited is the UK subsidiary of Orion Corporation, a Finnish pharmaceutical company. The UK entity manages commercial operations for Orion's prescription medicines portfolio across therapy areas including neurology, respiratory disease, oncology and women's health. A biologics R&D centre opened at…